Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 4:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 117 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Histology Clear all
Terminated Phase 1Phase 2 Interventional Results available

RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer

NCT01217411
View directory record Official record
Conditions
Adult Solid Neoplasm, Extensive Stage Lung Small Cell Carcinoma, HER2/Neu Negative, HER2/Neu Positive, Male Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Recurrent Breast Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Recurrent Lung Small Cell Carcinoma, Recurrent Melanoma, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions
Cognitive Assessment, Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Stereotactic Radiosurgery, Whole-Brain Radiotherapy
Procedure · Drug · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Sep 11, 2026, 4:26 AM EDT
Terminated Phase 3 Interventional Results available

Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology

NCT00596830
View directory record Official record
Conditions
Carcinoma, Squamous Cell, Carcinoma, Adenosquamous, Carcinoma, Large Cell, Carcinoma, Non-Small-Cell Lung
Interventions
CP-751,871 (Figitumumab), Carboplatin, Paclitaxel
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
681 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
169
States / cities
Florence, Alabama • Huntsville, Alabama • Muscle Shoals, Alabama + 133 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2014 · Synced Sep 11, 2026, 4:26 AM EDT
Completed No phase listed Observational

Assessment of Cardiac Allograft Vasculopathy With Optical Coherence Tomography

NCT01527344
View directory record Official record
Conditions
Cardiac Allograft Vasculopathy
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Sep 11, 2026, 4:26 AM EDT
Completed Phase 3 Interventional Results available

A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer

NCT01847274
View directory record Official record
Conditions
Ovarian Neoplasms, Platinum Sensitive Ovarian Cancer
Interventions
Active comparator: Niraparib, placebo
Drug
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
596 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
35
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2023 · Synced Sep 11, 2026, 4:26 AM EDT
Recruiting No phase listed Observational

Trifecta-Kidney cfDNA-MMDx Study

NCT04239703
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
MMDx, Prospera, HLA antibody
Diagnostic Test
Lead sponsor
University of Alberta
Other
Eligibility
Not listed
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
11
States / cities
Tampa, Florida • Baltimore, Maryland • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 11, 2026, 4:26 AM EDT
Recruiting Phase 2 Interventional

Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)

NCT06571708
View directory record Official record
Conditions
Bladder Cancer, Muscle-Invasive Bladder Carcinoma
Interventions
Gemcitabine, Cisplatin, Cemiplimab, Fianlimab
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 1, 2025 · Synced Sep 11, 2026, 4:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Influence of Bone Allograft Particle Sizes on the Quantity and Quality of New Bone Formation in Grafted Extraction Sockets and Edentulous Ridges

NCT03468998
View directory record Official record
Conditions
Alveolar Ridge Augmentation, Alveolar Ridge Preservation
Interventions
Socket Grafting with small particle allograft, Socket Grafting with large particle allograft, Lateral ridge augmentation with small particle allograft, Lateral ridge augmentation with large particle allograft
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 99 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 5, 2023 · Synced Sep 11, 2026, 4:26 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer

NCT04216316
View directory record Official record
Conditions
Lung Non-Small Cell Squamous Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions
Berzosertib, Biospecimen Collection, Carboplatin, Computed Tomography, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Pembrolizumab
Drug · Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
34
States / cities
Los Angeles, California • Newport Beach, California • Aventura, Florida + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 11, 2026, 4:26 AM EDT
Terminated No phase listed Observational

Intravascular Ultrasound Derived Virtual Histology and Intracoronary Serum Markers of Inflammation

NCT00982852
View directory record Official record
Conditions
Coronary Artery Disease, Atherosclerosis, Myocardial Infarction, Heart Failure, Angina
Interventions
Not listed
Lead sponsor
Quinn Capers
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 11, 2013 · Synced Sep 11, 2026, 4:26 AM EDT
Completed Phase 2 Interventional Results available

A Multi-Histology Phase II Study of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine (FdCyd + THU)

NCT00978250
View directory record Official record
Conditions
Head and Neck Neoplasms, Lung Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms
Interventions
5-Fluoro-2'-Deoxycytidine (FdCyd) + Tetrahydrouridine (THU)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
4
States / cities
Davis, California • Duarte, California • South Pasadena, California + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2019 · Synced Sep 11, 2026, 4:26 AM EDT
Completed Phase 2 Interventional Results available

Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer

NCT01693783
View directory record Official record
Conditions
Cervical Adenocarcinoma, Cervical Squamous Cell Carcinoma, Human Papillomavirus Infection, Recurrent Cervical Carcinoma, Stage IVA Cervical Cancer AJCC v6 and v7, Stage IVB Cervical Cancer AJCC v6 and v7
Interventions
Ipilimumab, Laboratory Biomarker Analysis
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
5
States / cities
Duarte, California • Sacramento, California • South Pasadena, California + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Sep 11, 2026, 4:26 AM EDT
Completed Phase 2 Interventional Results available

Copper Concentration & Histopathologic Changes in Liver Biopsy in Participants With Wilson Disease Treated With ALXN1840

NCT04422431
View directory record Official record
Conditions
Wilson Disease
Interventions
Bis-Choline Tetrathiomolybdate
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Sacramento, California • Ann Arbor, Michigan • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Sep 11, 2026, 4:26 AM EDT
Recruiting Phase 4 Interventional

Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study

NCT07405086
View directory record Official record
Conditions
Advanced Biliary Tract Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hepatocellular Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma, Advanced Renal Cell Carcinoma, Metastatic Biliary Tract Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hepatocellular Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Biospecimen Collection, Immune Checkpoint Inhibitor
Procedure · Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 11, 2026, 4:26 AM EDT
Completed No phase listed Observational

Protocol for the Assessment of Variability in Histology and Gene Expression in Bariatric Surgery Patients.

NCT00280527
View directory record Official record
Conditions
Obesity
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 19, 2011 · Synced Sep 11, 2026, 4:26 AM EDT
Completed Phase 3 Interventional Results available

Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer

NCT00686959
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Pemetrexed, Cisplatin, Etoposide, Vinorelbine, Paclitaxel, Carboplatin, Thoracic Radiation Therapy (TRT)
Drug · Radiation
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
598 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
50
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2016 · Synced Sep 11, 2026, 4:26 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Effects of Arzoxifene on Bone Mass and the Uterus

NCT00085956
View directory record Official record
Conditions
Postmenopausal Bone Loss
Interventions
Arzoxifene, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years to 60 Years · Female only
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 8, 2007 · Synced Sep 11, 2026, 4:26 AM EDT
Completed No phase listed Observational

HIV-HCV Coinfection: Impact of Immune Dysfunction

NCT00575315
View directory record Official record
Conditions
HIV Infections, Hepatitis
Interventions
Not listed
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 90 Years
Enrollment
634 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 19, 2014 · Synced Sep 11, 2026, 4:26 AM EDT
Withdrawn Not applicable Interventional

Effect of a Change in HIV Therapy on Liver Steatosis, Inflammation, and Fibrosis

NCT00023218
View directory record Official record
Conditions
HIV Infections, Hepatitis C
Interventions
Lopinavir/Ritonavir, Efavirenz
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Honolulu, Hawaii • Tripler AMC, Hawaii • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 8, 2015 · Synced Sep 11, 2026, 4:26 AM EDT
Active, not recruiting Phase 2 Interventional

Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma

NCT03541902
View directory record Official record
Conditions
Malignant Neoplasms of Urinary Tract, Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions, Sarcomatoid Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8, Unclassified Renal Cell Carcinoma
Interventions
Cabozantinib, Sunitinib Malate
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
3
States / cities
Houston, Texas • Sugar Land, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 11, 2026, 4:26 AM EDT
Withdrawn Phase 2 Interventional

Study of Lenvatinib in Patients With Advanced Cancer and Aberrations in FGF/FGFR Signaling

NCT02846766
View directory record Official record
Conditions
Cancer
Interventions
Lenvatinib
Drug
Lead sponsor
Teresa Helsten, MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
La Jolla, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Sep 11, 2026, 4:26 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS

NCT06008093
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Durvalumab, Tremelimumab, Pemetrexed, Pembrolizumab, Carboplatin, Cisplatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
47
States / cities
Beverly Hills, California • La Jolla, California • Los Alamitos, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 11, 2026, 4:26 AM EDT
Not listed Not applicable Interventional

Prospective Study for Evaluating Colon Polyp Histology With in Vivo Probe Based Confocal Laser Endomicroscopy

NCT01214031
View directory record Official record
Conditions
Colon Polyps, Adenomatous Polyps, Colon Cancer
Interventions
Confocal laser endomicroscopy (CLE)
Device
Lead sponsor
Midwest Biomedical Research
Other
Eligibility
18 Years to 85 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 8, 2012 · Synced Sep 11, 2026, 4:26 AM EDT
Not listed Not applicable Interventional

Histology Study of Biostimulatory Activity of Injectable Poly-L-Lactic Acid (Sculptra Aesthetic)

NCT04957446
View directory record Official record
Conditions
Nasolabial Fold, Facial Wrinkles
Interventions
Sculptra Aesthetic, Placebo
Device · Other
Lead sponsor
Sadick Research Group
Other
Eligibility
30 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 10, 2021 · Synced Sep 11, 2026, 4:26 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia

NCT00463385
View directory record Official record
Conditions
Myelofibrosis With Myeloid Metaplasia, Myeloid Metaplasia, Myelofibrosis
Interventions
Pomalidomide, Prednisone, Placebo to pomalidomide, Placebo to prednisone
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
6
States / cities
Los Angeles, California • Rochester, Minnesota • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Sep 11, 2026, 4:26 AM EDT